Invasive pneumococcal disease in Latin America and the Caribbean: Serotype distribution, disease burden, and impact of vaccination. A systematic review and meta …
A Bardach, S Ruvinsky, MC Palermo, T Alconada… - PLoS …, 2024 - journals.plos.org
Background Invasive pneumococcal diseases (IPD) are associated with high morbidity,
mortality, and health costs worldwide, particularly in Latin America and the Caribbean (LAC) …
mortality, and health costs worldwide, particularly in Latin America and the Caribbean (LAC) …
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children
J Ryman, J Weaver, KL Yee, JR Sachs - Expert review of vaccines, 2022 - Taylor & Francis
Background The potential impact of new pneumococcal conjugate vaccines (PCVs) is
assessed by using immune responses to predict their effectiveness against invasive …
assessed by using immune responses to predict their effectiveness against invasive …
Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children …
MD Wasserman, J Perdrizet, L Grant, K Hayford… - Infectious diseases and …, 2021 - Springer
Introduction The widespread implementation of pneumococcal conjugate vaccines (PCVs)
has significantly reduced the burden of pneumococcal disease around the world. Although …
has significantly reduced the burden of pneumococcal disease around the world. Although …
[HTML][HTML] A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up …
N Banniettis, J Wysocki, L Szenborn, W Phongsamart… - Vaccine, 2022 - Elsevier
Background Despite widespread use of pneumococcal conjugate vaccines (PCVs) in
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …
children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In …
Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published …
S Arya, N Norton, P Kaushik… - Human Vaccines & …, 2023 - Taylor & Francis
Despite widespread use of pneumococcal vaccines throughout Europe, the burden of
pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National …
pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National …
Incidence of pneumococcal disease from 2003 to 2019 in children≤ 17 years in England
S Mohanty, B Podmore, A Cuñado Moral, I Matthews… - Pneumonia, 2023 - Springer
Background Pneumococcal disease is a leading cause of communicable disease morbidity
and mortality globally. We aimed to estimate invasive pneumococcal disease (IPD) …
and mortality globally. We aimed to estimate invasive pneumococcal disease (IPD) …
Cost-effectiveness of pneumococcal vaccination in adults in Italy: comparing new alternatives and exploring the role of GMT ratios in informing vaccine effectiveness
In Italy, a sequential pneumococcal vaccination with conjugate vaccine (PCV) and
polysaccharide vaccine (PPSV23) is recommended for individuals aged≥ 65 years and …
polysaccharide vaccine (PPSV23) is recommended for individuals aged≥ 65 years and …
[HTML][HTML] Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review
NX Vo, HL Pham, UM Bui, HT Ho, TT Bui - Healthcare, 2024 - mdpi.com
Background: Open Access Systematic Review Cost-Effectiveness Analysis of Pneumococcal
Vaccines in the Pediatric Population: A Systematic Review by Nam Xuan Vo 1,*, Huong Lai …
Vaccines in the Pediatric Population: A Systematic Review by Nam Xuan Vo 1,*, Huong Lai …
The economic burden of pneumococcal disease in children: A population-based investigation in the Veneto region of Italy
E Barbieri, G Porcu, T Petigara, F Senese, GM Prandi… - Children, 2022 - mdpi.com
Despite widespread childhood immunization programs, pneumococcal disease (PD)
continues to be associated with significant clinical and economic burden worldwide. This …
continues to be associated with significant clinical and economic burden worldwide. This …
Healthcare resource utilisation and cost of pneumococcal disease from 2003 to 2019 in children≤ 17 years in England
S Mohanty, B Podmore, A Cuñado Moral, I Matthews… - Plos one, 2023 - journals.plos.org
Objective To estimate healthcare resource utilisation (HCRU) and costs associated with
pneumococcal disease (PD) in children aged≤ 17 years in England from 2003–2019 …
pneumococcal disease (PD) in children aged≤ 17 years in England from 2003–2019 …